Plexus International
This article was originally published in The Gray Sheet
Executive Summary
Receives May 4 warning letter from FDA for promotional claims of the company's MyoPlex 6000 muscle stimulator. Statements that the Myo-Plex provides "'[relief] of pain; removal of edema; muscle relaxation; rehabilitation of injured tissues'"; and other claims, "extend beyond the original intended use of a muscle stimulator," the agency contends. Plexus also is cited for failing to submit the necessary premarket notification for the device. The Houston, Texas-based company is the subject of an investigation by the ABC television show 20/20
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.